PRAX
Praxis Precision Medicines, Inc.
$314.56
-10.43 (-3.21%)
At close · Jul 13
Market Cap
$9.14B
Shares
27,878,774
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2025
Net Income
-$303.27M
-65.9%
FY2025
Operating Margin
-2340.29%
+2824.1pp
FY2024
Diluted EPS
-$13.48
-32%
FY2025
Operating Cash Flow
-$249.07M
-89%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | $0 | $8.55M | $2.45M | — | — | — | |
| $284.3M | $267.12M | $152.41M | $86.77M | $155.04M | $120.26M | $44.98M | |
| $73.03M | $59.08M | $56.31M | $42.05M | $59.95M | $47.08M | $16.99M | |
| $357.33M | $326.2M | $208.72M | $128.82M | $214.99M | $167.33M | $61.97M | |
| -$357.33M | -$326.2M | -$200.17M | -$126.37M | -$214.99M | -$167.33M | -$61.97M | |
| — | — | -2340.29% | -5164.41% | — | — | — | |
| $30.8M | $22.93M | $17.35M | $3.1M | $957K | $271K | $140K | |
| $0 | $0 | $0 | — | — | — | — | |
| — | -$302.8M | — | — | — | -$167.06M | -$61.83M | |
| — | $471K | — | — | — | $0 | -$8000 | |
| -$326.53M | -$303.27M | -$182.82M | -$123.28M | -$214.03M | -$167.06M | -$61.82M | |
| — | — | -2137.48% | -5037.88% | — | — | — | |
| — | — | — | — | — | -$167.06M | -$70.32M | |
| -$328.79M | -$303.36M | -$182.17M | -$123.1M | -$214.03M | -$167.24M | — | |
| USD/shares | — | -$13.48 | -$10.21 | -$18.69 | -$69.60 | -$59.10 | — |
| USD/shares | — | -$13.48 | -$10.21 | -$18.69 | -$69.60 | -$59.10 | — |
| shares | — | 22.5M | 17.91M | 6.59M | 3.07M | 2.83M | 596.68K |
| shares | — | 22.5M | 17.91M | 6.59M | 3.07M | 2.83M | 596.68K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.34×
EV/EBIT
—
Biotechnology median 25.45×
P/E (TTM)
—
Biotechnology median 7.56×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Reportable Segment | $0 | $8,553,000 | $2,447,000 |